Sangamo Therapeutics Inc (NASDAQ:SGMO) has a beta value of 1.21 and has seen 1.74 million shares traded in the recent trading session. The company, currently valued at $108.47M, closed the recent trade at $6720000.0 per share which meant it gained $6719999.54 on the day or 1739474% during that session. The SGMO stock price is 100.0% off its 52-week high price of $3.18 and 100.0% above the 52-week low of $0.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.77 million shares traded. The 3-month trading volume is 6.72 million shares.
The consensus among analysts is that Sangamo Therapeutics Inc (SGMO) is Hold stock at the moment, with a recommendation rating of 1.71. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 3 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Over the past 30 days, the shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) have changed -11.60%. Short interest in the company has seen 31.01 million shares shorted with days to cover at 6.62.
Wall Street analysts have a consensus price target for the stock at $2.5, which means that the shares’ value could drop -268799900.0% from the levels at last check today.. The projected low price target is $2.0 while the price target rests at a high of $3.0. In that case, then, we find that the latest price level in today’s session is 100.0% off the targeted high while a plunge would see the stock lose 100.0% from the levels at last check today..
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
The company’s shares have lost -84.33% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.57% over the past 5 years. Earnings growth for 2025 is a modest 25.07% while over the next 5 years, the company’s earnings are expected to increase by 20.66%.
SGMO Dividends
Sangamo Therapeutics Inc is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Insiders own 2.84% of the company shares, while shares held by institutions stand at 22.34% with a share float percentage of 23.00%. Investors are also buoyed by the number of investors in a company, with Sangamo Therapeutics Inc having a total of 152.0 institutions that hold shares in the company. The top two institutional holders are WASATCH ADVISORS LP with over 20.09 million shares worth more than $7.2 million. As of 2024-06-30, WASATCH ADVISORS LP held 9.8509% of shares outstanding.
The other major institutional holder is ARMISTICE CAPITAL, LLC, with the holding of over 14.06 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.04 million and represent 6.894% of shares outstanding.
